INT152666

Context Info Confidence 0.06 First Reported 2006 Last Reported 2008 Negated 0 Speculated 0 Reported most in Body Documents 2 Total Number 3 Disease Relevance 0.52 Pain Relevance 0.14

nucleoplasm (CREBBP) small molecule metabolic process (CREBBP) protein complex assembly (CREBBP) DNA binding (CREBBP) cytoplasm (CREBBP) signal transducer activity (CREBBP)

CREBBP (Homo sapiens)

Pain Link Frequency Relevance Heat antagonist 14 87.92 cINOD 26 5.00 aspirin 14 5.00 Kinase C 12 5.00 Inflammation 5 5.00 agonist 4 5.00 Arthritis 4 5.00 withdrawal 2 5.00 diclofenac 2 5.00 vincristine 2 5.00

Disease Link Frequency Relevance Heat Apoptosis 36 87.04 Colon Cancer 20 85.52 Pain 1 72.04 Disease 37 71.80 INFLAMMATION 5 71.44 Diabetes Mellitus 5 70.56 Cancer 162 62.72 Rheumatoid Arthritis 16 40.64 Colorectal Cancer 36 5.00 Familial Adenomatous Polyposis 14 5.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

The compound (ICG-001; Figure 4) described by Kahn et al. showed specific affinity and inhibition of CBP, and proved effective in preventing CBP-mediated transcriptional activation and ?

Negative_regulation (inhibition) of CBP

1) Confidence 0.06 Published 2006 Journal Invest New Drugs Section Body Doc Link PMC2780666 Disease Relevance 0.24 Pain Relevance 0.06

-catenin/Tcf4 transcriptional pathway by inhibiting cyclic AMP response element-binding protein (CBP) (Figure 4) [70, 171].

Negative_regulation (inhibiting) of CBP

2) Confidence 0.06 Published 2006 Journal Invest New Drugs Section Body Doc Link PMC2780666 Disease Relevance 0 Pain Relevance 0.09

RESULTS: RRME inhibited both p300 and CBP (60-70% at 100 microg/ml) activity.

Negative_regulation (inhibited) of CBP

3) Confidence 0.03 Published 2008 Journal J Ethnopharmacol Section Body Doc Link 18562138 Disease Relevance 0.29 Pain Relevance 0

General Comments

This test has worked.